The Loss of the p53 Activator HIPK2 Is Responsible for Galectin-3 Overexpression in Well Differentiated Thyroid Carcinomas-Reference-Cited by-同舟云学术

The Loss of the p53 Activator HIPK2 Is Responsible for Galectin-3 Overexpression in Well Differentiated Thyroid Carcinomas

Published:2011-06-17 Issue:6 Volume:6 Page:e20665
ISSN:1932-6203
Container-title:PLoS ONE
language:en
Short-container-title:PLoS ONE

Author:

Lavra Luca,Rinaldo Cinzia,Ulivieri Alessandra,Luciani Emidio,Fidanza Paolo,Giacomelli Laura,Bellotti Carlo,Ricci Alberto,Trovato Maria,Soddu Silvia,Bartolazzi Armando,Sciacchitano Salvatore

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference43 articles.

1. HIPKs: Jack of all trades in basic nuclear activities.;C Rinaldo;Biochimica et Biophysica Acta,2008

2. Homeodomain-interacting protein kinase-2 phosphorylates p53 at Ser 46 and mediates apoptosis.;G D'Orazi;Nat Cell Biol,2002

3. Regulation of p53 activity by its interaction with homeodomain-interacting protein kinase-2.;TG Hofmann;Nat Cell Biol,2002

4. HIPK2: a versatile switchboard regulating the transcription machinery and cell death.;MA Calzado;Cell Cycle,2007

5. HIPK2: a multitalented partner for transcription factors in DNA damage response and development.;C Rinaldo;Biochem Cell Biol,2007

Cited by 52 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. HIPK2 in Colon Cancer: A Potential Biomarker for Tumor Progression and Response to Therapies;International Journal of Molecular Sciences;2024-07-12

2. Correlation Analysis of Genetic Mutations and Galectin Levels in Breast Cancer Patients;Genes;2024-06-20

3. REST-restrained lncRNA EPB41L4A-AS2 Modulates Laryngeal Squamous Cell Carcinoma Development via Regulating miR-1254/HIPK2 Pathway;Current Protein & Peptide Science;2023-11

4. HIPK2 in the physiology of nervous system and its implications in neurological disorders;Biochimica et Biophysica Acta (BBA) - Molecular Cell Research;2023-06

5. Galectins as pivotal components in oncogenesis and immune exclusion in human malignancies;Frontiers in Immunology;2023-02-03